Vanguard reports 8.27M shares (7.53%) of Quest Diagnostics
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 8,274,567 shares of Quest Diagnostics Inc Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 8,274,567 shares of Quest Diagnostics Inc Common Stock. The filing states this equals 7.53% of the class as of 03/31/2026, with 1,128,895 shares for which Vanguard has sole voting power and 8,274,567 shares for which it has sole dispositive power. The filing lists affiliated Vanguard entities and notes holdings include securities held for Vanguard funds and managed accounts.
Insights
Large passive stake disclosed: 8,274,567 shares (7.53%).
Vanguard Capital Management reports a non‑operatorial, beneficial holding representing 7.53% of Quest Diagnostics common stock as of 03/31/2026. The filing attributes voting and dispositive powers across Vanguard affiliates and managed funds.
Because Schedule 13G filings are generally passive disclosures, this is a snapshot of ownership structure; subsequent filings could show changes in percent or voting intent.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned regulatory
Sole dispositive power regulatory
Investment Company Act regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Vanguard Capital Management report in Quest Diagnostics (DGX)?
Is Vanguard acting as an active investor in Quest Diagnostics per this filing?
What CUSIP and class are reported for Quest Diagnostics in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.